Information for Healthcare Professionals: Cefepime (marketed as Maxipime)
FDA ALERT [06/17/2009]:

The purpose of this communication is to share information about the FDA’s continuing safety review about the potential increased mortality in patients treated with cefepime. Cefepime is a cephalosporin antibacterial and is a member of the β–lactam class of antibacterial drugs. Cefepime is currently approved for the treatment of a variety of infections due to susceptible strains of microorganisms.
FDA performed meta-analyses based on additional data beyond those included in the Yahav et al. publication. In the FDA analyses, no statistically significant increase in mortality was seen in cefepime-treated patients compared to comparator-treated patients.
Based on the results of FDA's meta-analyses, the FDA has determined that cefepime remains an appropriate therapy for its approved indications.


FDA Analyses: The FDA performed meta-analyses based on both trial-1 and patient-level 2data. Data were derived from all available cefepime comparative clinical trials with evaluable data available to the FDA. In order to include trials in which there were no deaths in both treatment groups, the FDA used the Mantel-Haenszel risk difference method stratified by trial to estimate the risk of mortality in the trials—this is different from the risk ratio method used by Yahav et al.
Trial-level meta-analysis: The FDA’s trial-level meta-analysis included data from 88 clinical trials – the 38 trials that were included in the Yahav et al. meta-analysis, plus data from an additional 50 trials. These 88 trials included 9,467 cefepime-treated patients and 8,288 comparator-treated patients. No statistically significant difference in mortality was observed between cefepime and the comparators in the FDA trial-level meta-analysis.
All-cause mortality rates at 30-days post-therapy were 6.21% (588/9467) for cefepime-treated patients and 6.00% (497/8288) for comparator-treated patients with adjusted risk difference = 5.38 per 1000 population (95% C.I.: -1.53, 12.28).



Community Medicine Toolbox, Copyright © 2003, 2007-2019 地域医療ジャーナル